Cannabigerol (CBG)

Tier 3 — weak evidence · Cannabinoid · Anti-inflammatory · Focus

A non-intoxicating phytocannabinoid known as the 'mother cannabinoid' because CBGA is the biosynthetic precursor from which THCA, CBDA, and CBCA are derived. CBG acts at CB1/CB2 receptors weakly but more strongly at alpha-2 adrenergic, 5-HT1A, and TRPA1/TRPV1 channels. Preclinical evidence is strong for anti-inflammatory, antibacterial (including MRSA), and appetite-stimulating effects. Human trials are early but emerging data suggest focus, mood, and IBD symptom benefits. Legal status varies by jurisdiction — check local laws.

Dose: 10–50 mg per dose; product strength varies widely — start low